Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $38.06 in the prior trading day, Mineralys Therapeutics Inc (NASDAQ: MLYS) closed at $38.01, down -0.13%. In other words, the price has decreased by -$0.13 from its previous closing price. On the day, 0.93 million shares were traded. MLYS stock price reached its highest trading level at $39.3 during the session, while it also had its lowest trading level at $37.5.
Ratios:
Our goal is to gain a better understanding of MLYS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.12 and its Current Ratio is at 15.12. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Jefferies on June 11, 2025, initiated with a Hold rating and assigned the stock a target price of $15.
On July 10, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30.
On April 02, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $30.Goldman initiated its Buy rating on April 02, 2024, with a $30 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 15 ’25 when Rodman David Malcom sold 11,367 shares for $36.00 per share. The transaction valued at 409,266 led to the insider holds 81,524 shares of the business.
Rodman David Malcom bought 11,367 shares of MLYS for $409,266 on Sep 15 ’25. On Sep 04 ’25, another insider, AKKARAJU SRINIVAS, who serves as the Director of the company, bought 588,235 shares for $25.50 each. As a result, the insider paid 14,999,992 and bolstered with 588,235 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MLYS now has a Market Capitalization of 2948423936 and an Enterprise Value of 2194963968.
Stock Price History:
The Beta on a monthly basis for MLYS is 0.41, which has changed by 1.794853 over the last 52 weeks, in comparison to a change of 0.1719923 over the same period for the S&P500. Over the past 52 weeks, MLYS has reached a high of $41.09, while it has fallen to a 52-week low of $8.24. The 50-Day Moving Average of the stock is 47.81%, while the 200-Day Moving Average is calculated to be 133.71%.
Shares Statistics:
The stock has traded on average 1.52M shares per day over the past 3-months and 1421260 shares per day over the last 10 days, according to various share statistics. A total of 65.73M shares are outstanding, with a floating share count of 50.57M. Insiders hold about 34.81% of the company’s shares, while institutions hold 64.66% stake in the company. Shares short for MLYS as of 1757894400 were 7579857 with a Short Ratio of 4.98, compared to 1755216000 on 7408973. Therefore, it implies a Short% of Shares Outstanding of 7579857 and a Short% of Float of 12.280000000000001.
Earnings Estimates
. The current rating of Mineralys Therapeutics Inc (MLYS) reflects the combined expertise of 7.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.62, with high estimates of -$0.48 and low estimates of -$0.82.
Analysts are recommending an EPS of between -$2.35 and -$3.44 for the fiscal current year, implying an average EPS of -$2.72. EPS for the following year is -$2.65, with 7.0 analysts recommending between -$1.89 and -$3.43.
